Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis (Q40191979)

18 September 2017

Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis (English)

1 reference

18 September 2017

0 references

0 references

3

1 reference

18 September 2017

6

1 reference

18 September 2017

2

Toonen EJ

1 reference

18 September 2017

Marieke J H Coenen

1

1 reference

18 September 2017

Timothy R D J Radstake

series ordinal

4

1 reference

18 September 2017

Pilar Barrera

series ordinal

5

1 reference

18 September 2017

language of work or name

English

0 references

publication date

1 July 2007

1 reference

18 September 2017

1 reference

18 September 2017

8

1 reference

18 September 2017

7

1 reference

18 September 2017

761-773

1 reference

Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit

18 September 2017

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Clinical pharmacokinetics of TNF antagonists: how do they differ?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Interleukin-10 microsatellite polymorphisms and IL-10 locus alleles in rheumatoid arthritis susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Dissecting the genetic complexity of the association between human leukocyte antigens and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Tumor necrosis factor a microsatellite polymorphism is associated with rheumatoid arthritis severity through an interaction with the HLA-DRB1 shared epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

21 January 2018

Genetic linkage studies

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Large scale evidence and replication: insights from rheumatology and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Uses and abuses of meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Patients, their doctors, nonsteroidal anti-inflammatory drugs and the perception of risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFalpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Shaking the tree: mapping complex disease genes with linkage disequilibrium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Genome-wide detection of human copy number variations using high-density DNA oligonucleotide arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

A common functional polymorphism (C-->A substitution at position -863) in the promoter region of the tumour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

An investigation of polymorphism in the interleukin-10 gene promoter.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Interleukin 10 secretion in relation to human IL-10 locus haplotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: differential effects on production and allele frequencies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

The Met-196 -> Arg variation of human tumor necrosis factor receptor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Fc gamma receptor III on human neutrophils. Allelic variants have functionally distinct capacities

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

The influence of a polymorphism at position -857 of the tumour necrosis factor gene on clinical response to etanercept therapy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Fcγ receptor type IIIA genotype and response to tumor necrosis factor α–blocking agents in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Predictors of response to anti-TNF- therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

Functional Analysis of a New Polymorphism in the Human TNF alpha Gene Promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.7.761

21 January 2018

Identifiers

DOI

10.2217/14622416.8.7.761

1 reference

18 September 2017

1 reference